Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold by Krasavin, Mikhail et al.
Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-
thiadiazole-2-carboxamide scaffold
Krasavin, M., Lukin, A., Zhurilo, N., Kovalenko, A., Zahanich, I., Zozulya, S., ... Tikhonova, I. G. (2016). Novel
free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-thiadiazole-2-carboxamide scaffold. Bioorganic &
Medicinal Chemistry, 24(13), 2954–2963. DOI: 10.1016/j.bmc.2016.04.065
Published in:
Bioorganic & Medicinal Chemistry
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2016 Elsevier Ltd. All rights reserved. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
http://creativecommons.org/licenses/by-nc-nd/4.0/,which permits distribution and reproduction for non-commercial purposes, provided the
author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:06. Nov. 2017
Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-
thiadiazole-2-carboxamide scaffold 
Mikhail Krasavin,* Alexey Lukin, Nikolay Zhurilo, Alexey Kovalenko, Ihor Zahanich, Sergey Zozulya, 
Daniel Moore, and Irina G. Tikhonova 
 
N N
S
OH
O
N
H
O
GPR40 EC50 = 5.93 µM
N N
S
OH
O
N
H
O
N N
S ON
H
O
OH
O
GPR40 EC50 = 0.76 µM
High plasma and metabolic stability
phenyl 
ring 
extension
F
GPR40 EC50 = 0.56 µM
Low plasma and metabolic stability
O
COOH
O
OS
O O TAK-875
 
 
 
 
 
 
 
Novel free fatty acid receptor 1 (GPR40) agonists based on 1,3,4-
thiadiazole-2-carboxamide scaffold 
Mikhail Krasavin,a, * Alexey Lukin,b Nikolay Zhurilo,b Alexey Kovalenko,b Ihor Zahanich,c Sergey 
Zozulya, c, d Daniel Moore,e and Irina G. Tikhonovae  
a Institutes of Chemistry and Translational Biomedicine, Saint Petersburg State University, Saint 
Petersburg, 199034 Russian Federation 
b Lomonosov Institute of Fine Chemical Tehnologies, Moscow Technological University, 86 
Vernadskogo Prospekt, Moscow, 117571 Russian Federation 
c Enamine Ltd, 78 Chervonotkatska, Kyiv 02094, Ukraine 
d Taras Shevchenko National University, 62 Volodymyrska, Kyiv 01033, Ukraine 
e Molecular Therapeutics, School of Pharmacy, Medical Biology Centre, Queen’s University Belfast, 
Belfast BT9 7BL, Northern Ireland, UK 
 
* Corresponding author; phone: + 7 931 3617872, fax: +7 812 428 6939. 
E-mail address: m.krasavin@spbu.ru 
 
ABSTRACT 
Free fatty acid receptor 1 (FFA1), previously known as GPR40 is a G protein-coupled receptor and a 
new target for treatment of type 2 diabetes.  Two series of FFA1/GPR40 agonists employing utilizing a 
1,2,41,3,4-thiadiazole-2-caboxamide scaffold in their structure have been investigatedwere synthetized. 
Both series offered significant improvement of the potency compared to the earlier previously described 
1,2,41,3,4-thiadiazole-based FFA1/GPR40 agonists and high selectivity for FFA1. Structural Molecular 
docking predicts new aromatic interactions with the receptor that improve agonistunderstanding of the 
basis for such an improvement potency has been gained. The lead compoundsmost potent compounds 
from both series have beenwere profiled for their in vitro ADME properties (plasma and metabolic 
stability, LogD, plasma protein binding, hERG binding and, CYP inhibition). One series suffered very 
rapid degradation in plasma and in presence of mouse liver microsomes.. However, the other series 
delivered a lead compound that displayed an excellenta reasonable ADME profile together with the 
improved FFA1 potency.  across the panel of tests on top of the improved FFA1/GPR40 agonist potency. 
Keywords: 
GPR40, free fatty acid receptor 1, FFA1, agonists, bioisosteric replacement, total polar surface area, 
cLogP, metabolic stability, aqueous solubility. 
 
1. Introduction 
Agonists of free fatty acid receptor 1 (FFA1, also known as GPR40 prior to its de-orphanizationng in 
2003) hold a particular promise have the potential to becomeare an attractive alternative to the currently 
used anti-diabetic agents, most of which lower glucose levels irrespective of the basal blood glucose 
concentration and can cause hypoglycemia.1 FFA1 is highly expressed in the insulin-expressing beta 
cells of the pancreas and increases insulin secretion in a glucose-dependent manner, thus reducing risk 
of causing hypoglycemia.Under normal glycemiahomeostasis, FFA1 expression (primarily, in 
pancreatic islets of Langerhans) is low and increases only in hyperglycemic state. At higher expression 
levels, activation of the receptor by small molecule agonists triggers a signaling cascade that raises the 
levels of insulin, lowers the glucose levels and, consequently, downregulates FFA1 itself.2 Thus, the 
new therapeutic approach does not carry the danger of causing hypoglycemia (i. e. bringing the blood 
glucose concentration to dangerously low levels). Development of FFA1 agonists could provide 
therefore a new class of therapeutic agents This has led to an extensive research effort aimed at 
developing a new class of agents to treat type 2 diabetes mellitus (T2DM).3 However, tThe area of 
FFA1agonist-based theraputic targeting therapy was adversely affected by the late-2013 discontinuation 
of phase III trial of Takeda’s first-in-class agent fasiglifam (TAK-875).4 At the time of writing this 
manuscript, merely one clinical trial of an FFA1 agonist (Piramal’s compound P11187 of the undisclosed 
structure) was conducted.5 The unexpected toxicity issues aside, the antidiabetic efficacy of TAK-875 
was established in the course of Takeda’s clinical investigation of the drugtrails, thereby providing the 
proof-of-principle for the entirely new therapeutic approach.6 At the time of writing this manuscript, 
merely one clinical trial of an FFA1 agonist (Piramal’s compound P11187 of the undisclosed structure) 
has been conducted.5 ThereforeIt is expected that, the future quest for efficacious and safe FFA1 agonists 
should primarily focus on tackling their liver toxicity profile.7  
The toxicity has been linked to the high lipophilicity of TAK-875 as well as most reported FFA1 
agonists.7 An iIncrease ining the total polar surface area (TPSA, Å2) of FFA1 agonists could, in principle, 
provide a straightforward solution to the problem. However, TAK-875 and many other advanced 
compounds of this class (such as Amgen’s AMG-837,8 and Eli Lilly’s LY28818353) are based on the  
3-[4-(benzyloxy)phenyl]propanoic acid core, which mimics the fatty acid endogenous ligands of the 
receptor (Figure 1). Hence, imparting too much polarity to a FFA1 agonist may simply render the ligand 
inactive.  
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Figure 1. Advanced GPR40 agonists containing the 3-[4-(benzyloxy)phenyl]propanoic acid core.  
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One effective approach to fine-tuning the lipophilicity profile of FFA1 agonists is to ‘decorate’ the 3-
phenylpropahoic acid scaffold with polar heterocyclic moieties.9 Alternatively, thise scaffold itself could 
be replaced with heterocyclic isosteres (as in Takeda’s compounds 110, 211 and 312 as well as Amgen’s 
indole-based compound 413 shown in Figure 2).  
Recently, we have reported on the design and synthesis of a series of compounds containing the 3-(1,3,4-
thiadiazol-2-yl)propionic acid moiety (cLogP = -0.09) in lieu of the 3-phenylpropanoic acid moiety 
(cLogP = 1.84).14 The best compound in the series (5) displayed moderate agonist potency against 
GPR40 FFA1 (EC50 = 5.93 µM) and an excellent in vitro ADMET profile (plasma protein binding, 
aqueous solubility and microsomal stability). The lower potency of 5 (compared, for example to TAK-
875, GPR40 EC50 = 0.014 µM15) can be rationalized by the overly polar character of the 1,2,41,3,4-
thiadiazole-2-carbozamide used in lieu of the (4-benzyloxy)phenyl  moiety (vide supra). In this work, 
we investigated two compound series that stem from the initial series (represented by compound 5): i. 
1,2,41,3,4-thiadiazole-2-carbozamides 6 designed to bring back the lipophilicity of the series 
(introduction of an additional phenyl ring results in a cLog P increase by two units16) and thus improve 
its potency; ii. 3-phenylpropanoic acids 7 containing the 1,2,41,3,4-thiadiazole-2-carbozamide 
periphery, designed with the same ‘polar appendage’ approach in mind as explored by us earlier9 (Figure 
3). 
Figure 2. Structures of heterocyclic analogs of 3-phenylpropanoic acid-based GPR40 agonists 1-4. 
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Figure 3 Two chemical series (6 and 7) explored in this work. 1,2,41,3,4-thiadiazole-2-carbozamide is 
highlighted. 
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2. Results and discussion 
Compounds 6a-e were synthesized from known 2-chloroacetamides 8 according to the previously 
reported protocol.14, 17 Treatment of 8 with elementary sulfur and morpholine (in the presence of Et3N) 
gave N-aryl-2-moropholino-2-thiooxacetamides 9. The latter furnished hydrazino adducts 10 on reaction 
with hydrazine hydrate. Isolated by simple filtration and without further purification (see Experimental 
section), these adducts were transformed, in good to excellent yields, into target compounds 6a-e on 
reaction with succinic anhydride in glacial acetic acid (Scheme 1). 
Scheme 1. Synthesis of 3-(1,2,41,3,4-thiadiazol-2-yl)propanoic acids 6a-e.  
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3-Phenylpropanoic acids 7a-l containing the 1,2,41,3,4-thiadiazole-2-carboxamide periphery were 
synthesized in a similar fashion from 2-chloroacetamides 11. The hydrazino adducts 12 were condensed 
(via CDI-promoted N-acylation and subsequent cyclodehydration on treatment with HCl) with [4-(3-
tert-butoxy-3-oxopropyl)phenoxy]acetic acid (13) which, in turn, was obtained by alkylation of 
commercially available tert-butyl 3-(4-hydroxyphenyl)propionate (14) with ethyl bromoacetate and 
subsequent ester hydrolysis (Scheme 2).  
Scheme 2. Synthesis of 3-phenylpropanoic acids 7a-l.  
NN
SO N
H
O
Cl
N
H
O
11
S8, morpholine
Et3N, DMF, r. t.
16-20 h
N2H4
hydrate
H
N
N
H
O
12
S
H2N
7a-l, 54-70% from 11
R
O
O O OH
OO
O OH
14 13, 70%
1) BrCH2COOEt,
    K2CO3, DMF
    60 oC, 10 h
2) KOH, H2O/MeOH
    r. t., 12 h
R
O
HO
CDI
DCM
r. t., 16 h
4M HCl
1,4-dioxane
r. t., 16 h
R
 
Both sets of potential GPR40 agonists (6a-e and 7a-l) were tested for FFA1 activation using a calcium 
flux assay conducted on Chinese hamster ovary (CHO) cells. All compounds were tested in 
concentration-response (% GPR40 activation) mode in order to determine EC50 values, which are 
presented in Table 1. 
Table 1. Structures, cChemical yields, and GPR40 activationactivitites data and lipophilicities of 
agonists 6a-e and 7a-l. 
Compound R Isolated yield (%) GPR40 EC50 ± SD, µM* cLogP16 
NN
S
HO
O
N
H
O R
 
6a 3-(3-MeC6H4) 82 0.76 ± 0.08 3.87 ± 0.64 
6b 3-(3-ClC6H4) 80 1.69 ± 0.12 3.98 ± 0.65 
6c 3-(4-FC6H4) 78 1.28 ± 0.15 3.35 ± 0.69 
6d 3-(2-furyl) 64 1.64 ± 0.12 2.72 ± 0.65 
6e BnO 76 17.94 ± 3.28 3.08 ± 0.65 
NN
SO N
H
O R
O
HO
 
7a H 60 1.06 ± 0.14 2.78 ± 0.64 
7b 4-MeO 62 >10.00 2.73 ± 0.64 
7c 2-F 58 0.58 ± 0.10 2.75 ± 0.64 
7d 3-Me 54 1.77 ± 0.17 3.24 ± 0.64 
7e 4-F 58 6.64 ± 1.87 3.23 ± 0.67 
7f 2-Me 56 1.52 ± 0.18 3.24 ± 0.64 
7g 4-Cl 63 3.69 ± 0.95 3.77 ± 0.64 
7h 3-F 55 1.19 ± 0.19 3.27 ± 0.67 
7i 3-MeO 62 4.68 ± 0.80 3.04 ± 0.64 
7j 3,4-diF 70 0.58 ± 0.09 3.62 ± 0.70 
7k 4-Me 54 4.30 ± 1.56 3.24 ± 0.64 
7l 3-Cl 54 10.62 ± 1.02 3.81 ± 0.65 
* Each value is an average of n = 4. 
In analyzing the data on biological activity against FFA1, it should be borne in mind that the anilide 
periphery in the series of the receptor agonists represented by compound 5 was designed so as to impart 
higher lipophilicity to otherwise overly hydrophilic 3-(1,2,41,3,4-thiadiazol-2-yl)propanoic acid 
scaffold (vide supra) and thus increase affinity to the receptor (the physiological activation of which is 
triggered by endogenous fatty acid ligands like eicosatienoic acid).18 From the data obtained for a even 
a small set (6a-e) of higher-logP analogs of compound 5, it becomes apparent that our hypothesis of 
using lipophilicity as a driver of potency against FFA1 was correct. Indeed, four out of five analogs had 
significantly higher potency compared to 5, (with the best compound, 6a, leading into the sub-
micromolar range). The lower potency of 6e most is likely due to  conformational rigidity requirement 
in the portion of the molecule opposite to carboxylic acid functionality, which is present in biphenyl 
analogs 6a-d and is lost after introduction of the -CH2O- linker in 6e. 
The overall very satisfactory potency profile of compounds 7a-l suggests that 1,2,41,3,4-thiadiazole-2-
carboxamide moiety was a suitable periphery group to add to the 3-phenylpropanoic acid core in order 
to improve affinity to FFA1. The agonist activity in this series appears to be particularly sensitive to the 
substitutions in the anilide moiety, thus attesting for the importance of the latter for building efficient 
interactions with the receptor. Clearly, substitution in position 4 of the phenyl ring is particularly 
detrimental for the activity (7b, 7g, 7e, 7k). Substituents in positions 2 and 3 seem to be well tolerated, 
with one of twothe most active compounds (7c) having fluorine in position 2. The high potency of the 
3,4-difluorophenyl compound (7j) is somewhat surprising in light of the relatively low potency of the 4-
fluorophenyl compound (7e). 
It was important to establishWe next evaluated the selectivity profile of the most potent GPR40 agonists 
from both series studied here (6a, 6c, 7c and 7j) against other GPCRs binding free fatty acidsfree fatty 
acid receptors (FFA3/GPR41, FFA2/GPR43 and FFA4/GPR120). While the four FFARs share a 
significant similarity, GPR41 FFA2 and GPR43 FFA3 agonists are usuallyhave a preference in binding 
shorter short-chain fatty acids while GPR40 FFA1 and GPR120 FFA4 have a higher affinity to medium- 
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and long-chain fatty acids.19,20 As it is seen from the activation activity data against this panel of 
GPRsGPCRs, the four lead compounds displayed high selectivity for GPR40 FFA1 (Table 2).  
Table 2. Selectivity profile for compounds 6a, 6c, 7c and 7j.a 
??? 6a 6c 7c 7j 
human FFA1/GPR40 EC50 (µM) 0.76 1.28 0.58 0.58 
human FFA3/GPR41 EC50 (µM) >10 >10 >10 >10 
human FFA2/GPR43 EC50 (µM) >10 >10 >10 >10 
human FFA4/GPR120 EC50 (µM) >10 >10 >10 >10 
a Each values is an average of n = 4 in the presence of 0.1% BSA.  
 
 
Figure 4.  Docked poses of compounds 5 and 6a at FFA1.*  
 
* (A) Overlay of 5 and 6a in the FFA1 binding site. Compounds 5 and 6a are in magenta cyan and yellow 
magenta color, respectively. Protein-ligand interactions are visualized for compound 6a only. (B) 
Hydrophobic interactions of the terminal ring of compound 5 with FFA1. (C) Hydrophobic and π-π 
interactions of the biphenyl moiety of compound 6a with FFA1. Hydrogen bonds, π-π and hydrophobic 
interactions are in a brown, blue and yellow dashed-line, respectively. Residues are labeled with their 
position followed by the Ballesteros and Weinstein numbering.21. Transmembrane helices are labeled in 
red, Roman numerals. 
To gain a structural understanding of improved potency of 6a compared to 5, we have docked 6a and 5 
in the FFA1 binding site. As visualized in Figure 4A, both compounds have a similar orientation within 
the binding cavity forming hydrogen bonds with R1835.39, Tyr913.37, Tyr2406.51 and the backbone of 
L1384.57. While the more potent agonists (TAK-875, AMG 837 and LY2881835) substitute the 1,3,4-
thiadizole with a more hydrophobic benzene ring, thiadizole is still well accommodated within the 
binding site. This can be justified by its propensity to form π-π interactions with W174EL2 and possibly 
F873.33. 
The phenyl ring of 5 is at the interhelical space of helices 3 and 4, forming hydrophobic interactions 
with V843.30 , F883.34 and F1424.61 (Figure 4B). In contrast, the same phenyl ring of 6a positions deeper 
within the binding cavity forming π-π stacking interactions with F883.34 and F1424.61 (Figure 4C). It 
appears that the addition of a second phenyl ring in 6a slightly pulls the molecule inside the helical 
bundle. This is due to involvement of the second phenyl ring in hydrophobic interactions with V843.30 
and L1354.54 and the π-π stacking interaction with F883.34.  The formation of the aromatic network with 
the receptor could explain the 10-fold increase in potency observed for 6a compared to 5.  
Figure 5. Overlay of the docked pose of compound 7c (orange) with the crystal structure conformation 
of TAK-875 (green) in the FFA1 binding site.*  
 
* Protein-ligand interactions are visualized for compound 7c only. Hydrogen bonds, π-π and 
hydrophobic interactions are in a brown, blue and yellow dashed-line, respectively. Residues are labeled 
with their position followed by the Ballesteros and Weinstein numbering.21 . Transmembrane helices are 
labeled in red, Roman numerals. 
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The portion of 7a-l bearing the carboxylic acid functionality is similar to the 3-[4-
(benzyloxy)phenyl]propanoic acid core of TAK-875. To investigate the conformational similarities 
between 7c (one of the most potent compounds in the series) and the TAK-875 co-crystallized with the 
receptor, both were docked onto FFA1 (Figure 5). Indeed, the hydrophobic benzene ring of the 3-
phenylpropanoic acid portion of 7c appears beneficial for agonist activity as it matches the hydrophobic 
environment of the active site. The position of 7c inside the binding cavity closely resembles that of 
TAK-875. However, the differences in activity is likely attributable to the variation of the agonist 
aromatic tail. The 2-fluorobenzene tail of 7c points straight to the lipid side, whereas in TAK-875, the 
2,6-dimethylphenyl moiety of TAK-875 points toward the extracellular side of the lipids. The two 
methyl substituents control the dihedral angle of the biphenyl portion of TAK-875.Methyl substitutions 
at position 3 keeps two aromatic rings at an angle to each other. As a result, TAK-875 forms additional 
favorable π-π stacking contacts with F1424.61. In contrast, the terminal ring of 7c connected via a rigid 
planar amide group extends straight and forms , similarly to 6a (vide supra), hydrophobic interactions 
with P803.26, V813.27 and V843.30.  It appears that the terminal ring of 7c is particularly prone to steric 
effects. Indeed, even moderately bulky substituents (such as those present in 7b, 7d, 7f, 7i and 7k) tend 
to lower the agonist potency.  
Table 3. The in vitro ADME profile of compounds 6a, 6c, 7c and 7l.  
Physicochemical properties 6a 6c 7c 7l 
Plasma stability (mouse) - T1/2, min >240 >240 20.4 115.7 
Plasma protein binding (mouse) - % bounda 92.4 94.1 NDb 92.8 
Metabolic stability (mouse liver 
microsomes) 
T1/2, min 77.5 208.9 6.9 13.2 
CLint, µL/min/mg 21.6 8.0 241.4 126.3 
LogD, pH 7.4a 1.28 0.96 0.95 1.46 
a Each value is an average of n = 2, measured at c = 1 µM. 
b Data were inconclusive due to compound’s low plasma stability. 
Since we were able to reach low micromolar to sub-micromolar potency in both compound series (6 and 
7), we were also keen on in assessing the preliminary ADME profile, (particularly with respect to plasma 
and liver microsomal stability) forof the most active compounds from these series. As it is evident from 
Table 3, all compounds demonstrated very favorable octanol-water distribution properties (LogD 
measured at pH 7.4) which were are well within the limits of established for developable drug 
candidates.22 However, the metabolic and plasma stability of the two series differed significantly: 
compounds 6a and 6c displayed excellent stability (in line with our previous findings14) while 
compounds 7c and 7l were markedly unstable. This even hindered the determination of plasma protein 
binding for 7c, while the other three compounds displayed a good free fraction in plasma. The latter 
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unfortunate aspect (which could be related to the presence of metabolically prone 4-phenoxy-1,2,41,3,4-
thiadiazole linkage in 7a-l) will undoubtedly affect the prospects of developing compounds belonging 
to series 7 as pharmacological tools or drug candidates.   
Table 4. The hERG K+ channel binding profile (% ± SE)a of compounds 6a, 6c, 7c and 7l. 
 6a 6c 7c 7l 
20 µM 22.0 ± 3.6  -1.0 ± 5.7 4.0 ± 3.3 36.0 ± 6.8 
5 µM 2.0 ± 3.9 -1.0 ± 5.4 -7.0 ± 3.8 -3.0 ± 3.7 
1 µM 8.0 ± 4.5 -6.0 ± 3.3 9.0 ± 9.5 1.0 ± 8.9 
a Each value is an average of n = 4. 
The four lead compounds (6a, 6c, 7c, 7l) displayed very favorable hERG binding profile as determined 
using PredictorTM hERG Fluorescence Polarization Assay (see Experimental section). The modest 
binding of two compounds (6a and 7l) can be viewed as not significant in light of the much higher 
potency of the compounds. 
Table 5. The CYP450 inhibition profile (% inhibition ± SE)a of compounds 6a, 6c, 7c and 7l. 
CYP450 6a 6c 7c 7l 
1A2 94.3 ± 0.5 47.2 ± 9.8 18.8 ± 4.5 41.9 ± 9.2 
2C9 9.8 ± 9.9 -1.9 ± 5.8 12.8 ± 9.7 85.0 ± 4.9 
2C19 37.2 ± 5.9 25.2 ± 5.4 -3.3 ± 3.6 77.7 ± 1.3 
2D6 1.8 ± 9.2 11.8 ± 9.4 6.6 ± 14.5 22.7 ± 1.3 
3A4 12.3 ± 6.3 -5.1 ± 11.1 -28.7 ± 9.6 55.2 ± 2.9 
a Each value is an average of n = 4, measured at c =concentration 20 µM. 
The cytochrome P450 inhibition profile assessed for five principal isoforms (1A2, 2C9, 2C19, 2D6 and 
3A4)23 demonstrated that the occasional isoform-selective inhibition is not scaffold-related. Clearly, 
among two compounds in each series, compounds 6c and 7c have a markedly ‘cleaner’ profile and, 
hence, lower likelihood of causing drug-drug interactions due to CYP inhibition.24 
3. Conclusions 
We have explored two chemical series as FFA1 receptor agonists: one (6) in which 1,2,41,3,4-
thiadiazole-2-carboxamide plays the role of the core scaffold and the other (7) containing a 1,2,41,3,4-
thiadiazole-2-carboxamide moiety as a periphery group ‘decorating’ the 3-phenylpropanoic acid core 
(the latter is common for many known advanced FFA1 agonists). Both chemical series delivered 
compounds of sub-micromolar potency and excellent selectivity against a panel of other free fatty acid 
receptors (FFA2/GPR43, FFA3/GPR41 and FFA4/GPR120), confirming the correctness of the initial design 
idea. The observed SAR trends have also been rationalized by in silico docking of the most active 
compounds onto in FFA1, in comparison with the earlier described 1,2,41,3,4-thiadiazole-2-
carboxamide 5 and Takeda’s discontinued clinical candidate TAK-875. The best compounds in each 
series have been profiled for ADME parameters (plasma and metabolic stability, plasma protein binding, 
LogD (pH 7.4), CYP inhibition and hERG binding. Unfortunately, the low plasma and metabolic 
stability observed for the series 7 compounds tarnishes the series from developability perspectivefuture 
development. On the contraryIn contrast, series 6 displayed excellent plasma and metabolic stability, 
reasonable free fraction in plasma and a good CYP inhibition and hERG binding profile. Compound 6c 
clearly standsing out in terms of the overall potency and ADME profile. 
 
4. Experimental section 
4.1. General experimental 
All reactions were conducted in oven-dried glassware . Melting points were measured with a Buchi В-
520 melting point apparatus and were not corrected. Analytical thin-layer chromatography was carried 
out on Silufol UV-254 silica gel plates using appropriate mixtures of ethyl acetate and hexane. 
Compounds were visualized with short-wavelength UV light. 1H NMR and 13C NMR spectra were 
recorded on Bruker MSL-300 spectrometers in DMSO-D6-d6 using TMS as an internal standard. Mass 
spectra were recorded using Shimadzu LCMS-2020 system with electron impact (EI) ionization. All and 
reagents and solvents were obtained from commercial sources and used without purification. 
All mass-spectroscopic measurements required for determination of ADME properties were performed 
using Shimadzu VP HPLC system including vacuum degasser, gradient pumps, reverse phase HPLC 
column, column oven and autosampler. The HPLC system was coupled with tandem mass spectrometer 
API 3000 (PE Sciex). The TurboIonSpray ion source was used in both positive and negative ion modes. 
Acquisition and analysis of the data were performed using Analyst 1.5.2 software (PE Sciex). 
 
4.2.  Synthetic organic chemistry 
4.2.1. Starting materials 
2-Chloroacetamides 8 and 11 as well as tert-butyl 3-(4-hydroxyphenyl)propionate (14) are known and 
commercially available compounds. 
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4.2.1.1.  [4-(3-Tert-butoxy-3-oxopropyl)phenoxy]acetic acid (13). A 250 mL round-bottomed flask 
was charged with a solution of tert-butyl 3-(4-hydroxyphenyl)propionate (14, 7.15 g, 32.0 mmol) in 
anhydrous DMF (50 mL). Freshly calcinated K2CO3 (3.5 g, 25.0 mmol) was added in small portions 
followed by a dropwise addition of a solution of ethyl bromoacetate (7.0 g, 41 mmol) in DMF (20 mL). 
The reaction mixture was heated, on vigorous stirring, at 60 °C for 10 h. The solvent was removed in 
vacuo and the residue was poured into water. The aqueous phase was extracted with ethyl acetate (3 x 
100 mL). The combined organic extracts were washed with 5% aqueous HCl, 5% aqueous K2CO3 and 
brine, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. The redisue was dissolved in 
methanol (100 mL) and a solution of KOH (2.34 g) in water (10 mL) was added dropwise. The reaction 
mixture was stirred for 12 h at r. t. and the volatiles were removed in vacuo. The residue was dissolved 
in water (100 mL) and the solution was extracted with ethyl actetate (3 x 50 mL) and the organic extracts 
were discarded. The aqueous phase was carefully acidified to pH 5 with 5% aqueous HCl and extracted 
again with ethyl acetate (3 x 50 mL). The combined organic extracts were dried over anhydrous Na2SO4, 
filtered and concentrated in vacuo. The residue was purified by column chromatography on silica gel 
using 0  5% gradient of methanol in chloroform as eluent to provide the title compound as a white 
crystalline solid (6.2 g, 22.3 mmol, 70%). M. p. 73-78 °C; 1H NMR (300 MHz, CDCl3) δ 10.61 (s, 1H), 
7.14 (d, J = 8.6 Hz, 1H), 6.85 (d, J = 8.6 Hz, 2H), 4.66 (s, 1H), 2.86 (t, J = 7.7 Hz, 1H), 2.52 (t, J = 7.7 
Hz, 1H), 1.42 (s, 4H); 13C NMR (75 MHz, CDCl3) δ 174.11, 172.65, 155.89, 134.30, 129.51, 114.59, 
80.63, 64.94, 37.25, 30.25, 28.06; MS m/z  281.4  (M+H+). 
 
4.2.2. General procedure for the preparation of compounds 6a-e 
To a suspension of elementary sulfur (512 mg, 16.0 mmol) in dry DMF (20 mL) was sequentially added  
(in dropwise fashion) triethylamine (2.25 mL, 16.0 mmol) and morpholine (1.06 mmol) and the resulting 
mixture was stirred for 30 min. Then it was treated with a solution of respective 2-chloroacetamides 8 
(0.5 mmol). The mixture was stirred overnight, poured into water (50 mL) and the resulting precipitate 
was separated by filtration and air-dried. It was then suspended in acetone (50 mL) and the insoluble 
residue of excess of unreacted sulfur was filtered off and discarded. The filtrate was evaporated to 
dryness and the dry residue was dissolved in dry DMF (15 mL), treated with hydrazine hydrate (2.5 mL) 
and stirred for 12 hours. The reaction mixture was poured into water, the pH of the aqueous medium 
was adjusted to 5.0 with 2M aqueous HCl. The resulting precipitate of 10 was filtered off and used in 
the next step without further purification (purity of at least 90% was estimated based on 1H NMR 
analysis). Thiohydrazide 10 thus obtained was placed in a thick-walled crew-capped glass tube along 
with succinic anhydride (1.2 mmol) and glacial acetic acid (3.0 mL). The reaction mixture was heated 
at reflux temperature on vigorous stirring over 2 hours, cooled down and poured into water (25 mL). 
The precipitate formed was filtered off and air dried to deliver analytically pure compounds 6a-e in 
yields indicated. 
4.2.2.1. 3-{5-[(3'-methylbiphenyl-3-yl)carbamoyl]-1,3,4-thiadiazol-2-yl}propanoic acid (6a). 
Compound 6a was obtained as a white  solid (150 mg, 82%). M. p. 156-159 °С; 1H NMR (300 MHz, 
DMSO-d6) δ 12.41 (s, 1H), 11.17 (s, 1H), 8.17 (s, 1H), 7.84 (dd, J = 7.2, 3.7 Hz, 1H), 7.49 – 7.41 (m, 
4H), 7.37 (t, J = 7.5 Hz, 1H), 7.20 (d, J = 7.3 Hz, 1H), 3.40 (t, J = 6.9 Hz, 2H), 2.84 (t, J = 7.0 Hz, 2H), 
2.39 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 173.64, 172.86, 165.77, 156.35, 140.78, 139.80, 138.21, 
138.07, 129.24, 128.82, 128.24, 127.23, 123.71, 122.87, 119.61, 119.09, 32.71, 25.25, 21.06. HRMS 
(ESI) m/z calcd for C19H17N3O3SNa [M+Na+] 390.0883, found 390.0883. 
 
4.2.2.2. 3-{5-[(3'-chlorobiphenyl-3-yl)carbamoyl]-1,3,4-thiadiazol-2-yl}propanoic acid (6b). 
Compound 6b was obtained as a white  solid (155 mg, 80%). M. p. 159-162 °С; 1H NMR (300 MHz, 
DMSO-d6) δ 12.42 (s, 1H), 11.18 (s, 1H), 8.19 (s, 1H), 7.91 (d, J = 6.0 Hz, 1H), 7.69 (s, 1H), 7.63 (d, J 
= 7.5 Hz, 1H), 7.56 – 7.42 (m, 5H), 3.40 (t, J = 6.9 Hz, 2H), 2.84 (t, J = 7.0 Hz, 2H); 13C NMR (75 MHz, 
DMSO-d6) δ 173.79, 172.99, 165.79, 156.43, 141.98, 139.08, 138.40, 133.81, 130.88, 129.54, 127.53, 
126.37, 125.33, 123.03, 120.30, 119.19, 32.74, 25.31. HRMS (ESI) m/z calcd for C18H14ClN3O3SNa 
[M+Na+] ,410.0336, found 410.0337. 
 
4.2.2.3. 3-{5-[(4'-fluorobiphenyl-3-yl)carbamoyl]-1,3,4-thiadiazol-2-yl}propanoic acid (6c). 
Compound 6c was obtained as a white  solid (145 mg, 78%). M. p. 279-181 °С; 1H NMR (300 MHz, 
DMSO-d6) δ 11.79 (s, 1H), 8.76 (s, 1H), 8.46 (dd, J = 6.5, 2.2 Hz, 1H), 8.30 (dd, J = 8.7, 5.5 Hz, 2H), 
8.11 – 8.03 (m, 2H), 7.93 (t, J = 8.8 Hz, 2H), 4.01 (t, J = 6.9 Hz, 2H), 3.45 (t, J = 6.9 Hz, 2H); 13C NMR 
(75 MHz, DMSO-d6) δ 173.78, 173.00, 165.82, 161.99 (d, J = 244.63 Hz), 156.43, 139.69, 138.32, 
136.36 (d, J = 2.94 Hz), 129.43, 128.64 (d, J = 8.31 Hz), 122.93, 119.73, 119.07, 115.84 (d, J = 21.45 
Hz), 32.76, 25.31. HRMS (ESI) m/z calcd for C18H14FN3O3SNa 394.0632, found 394.0632. 
 
4.2.2.4. 3-(5-{[3-(furan-2-yl)phenyl]carbamoyl}-1,3,4-thiadiazol-2-yl)propanoic acid (6d). 
Compound 6d was obtained as a white  solid (110 mg, 64%). M. p. 218-221 °С; 1H NMR (300 MHz, 
DMSO-d6) δ 12.42 (s, 1H), 11.18 (s, 1H), 8.25 (s, 1H), 7.75 (dd, J = 12.8, 4.7 Hz, 2H), 7.51 (d, J = 7.8 
Hz, 1H), 7.42 (t, J = 7.9 Hz, 1H), 6.91 (d, J = 3.3 Hz, 1H), 6.61 (dd, J = 3.3, 1.8 Hz, 1H), 3.39 (t, J = 7.0 
Hz, 2H), 2.83 (t, J = 6.9 Hz, 2H); 13C NMR (75 MHz, DMSO-d6) δ 173.74, 172.98, 165.77, 156.46, 
152.69, 143.13, 138.30, 130.79, 129.38, 119.86, 119.81, 115.63, 112.14, 106.17, 32.72, 25.29.  HRMS 
(ESI) m/z calcd for C16H13N3O4SNa [M+Na+] 366.0519, found 366.0519. 
 
4.2.2.5. 3-(5-{[4-(benzyloxy)phenyl]carbamoyl}-1,3,4-thiadiazol-2-yl)propanoic acid (6e). 
Compound 6e was obtained as a white  solid (146 mg, 76%). M. p. 205-207 °С; 1H NMR (300 MHz, 
DMSO-d6) δ 12.42 (s, 1H), 11.00 (s, 1H), 7.74 (d, J = 8.6 Hz, 2H), 7.3 – 7.5 (m, 5H), 7.02 (d, J = 8.6 
Hz, 2H), 5.10 (s, 2H), 3.38 (t, J = 6.7 Hz, 2H), 2.82 (t, J = 6.7 Hz, 2H); 13C NMR (75 MHz, DMSO-d6) 
δ 173.89, 173.36, 166.45, 156.34, 155.74, 137.55, 131.41, 128.88, 128.27, 128.14, 122.76, 115.33, 
69.86, 33.24, 25.73. HRMS (ESI) m/z calcd for C19H17N3O4SNa [M+Na+] 406.0835, found 406.0837. 
 
4.2.3. General procedure for the preparation of compounds 7a-l 
Compounds 7a-l were prepared in the same manner and on the same scale (0.5 mmol of 2-
chloroacetanilides 11) as described above for the preparation of compounds 6a-e, except for the 
1,2,41,3,4-thiadiazole-forming step. To a solution of [4-(3-tert-butoxy-3-oxopropyl)phenoxy]acetic acid  
(13, 0.5 mmol, 140 mg) in DCM (4 mL) carbonyldiimidazole (0.55 mmol, 90 mg) was added and the 
mixture was stirred at r. t. for 30 min. To the resulting solution of the carboxylic acid imidazolide, 
thiohydrazide 12 (obtained in the reaction of 2-chloroacetanilide 11 with morpholine and elementary 
sulfur in the presence of Et3N followed by treatment with hydrazine hydrate) was added and the reaction 
mixture was stirred at r. t. for 16 h. The solvent was removed in vacuo, the residue was dissolved in 
glacial acetic acid (3 mL) and the solution was heated at reflux for 30 min. It was then cooled down to 
r. t., poured into water (50 mL) and the resulting precipitate was collected by filtration and dried in 
vacuo. It was then combined with 4M solution of HCl in 1,4-dioxane (5 mL); the mixture was stirred at 
r. t. for 16 h and poured into water (50 mL). The precipitate was collected by filtration, washed with 
water and air-dried to provide compound 7a-l in yields indicated. 
4.2.3.1. 3-(4-{[5-(Phenylcarbamoyl)-1,3,4-thiadiazol-2-yl]methoxy}phenyl)propanoic acid (7a). 
Compound 7a was obtained as a white  solid (115 mg, 60%). M. p. 199-206 °С; 1H NMR (300 MHz, 
DMSO-d6) δ 12.13 (s, 1H), 11.20 (s, 1H), 7.84 (d, J = 7.9 Hz, 2H), 7.38 (t, J = 7.8 Hz, 2H), 7.17 (dd, J 
= 11.5, 8.0 Hz, 3H), 7.01 (d, J = 8.5 Hz, 2H), 5.64 (s, 2H), 2.77 (t, J = 7.5 Hz, 2H), 2.50 (t, J = 7.5 Hz, 
2H); 13C NMR (75 MHz, DMSO-d6) δ 173.79, 171.65, 166.76, 156.03, 155.47, 137.66, 134.32, 129.45, 
128.79, 124.77, 120.83, 114.93, 64.31, 35.43, 29.49. HRMS (ESI) m/z calcd for C19H17N3O4SNa 
[M+Na+],406.0832, found 406.0832. 
 
4.2.3.2. 3-[4-({5-[(4-Methoxyphenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic 
acid (7b). Compound 7b was obtained as a white solid (128 mg, 62%). M. p. 198-203 °С; 1H NMR (300 
MHz, DMSO-d6) δ 12.12 (s, 1H), 11.09 (s, 1H), 7.76 (d, J = 7.9 Hz, 2H), 7.19 (d, J = 7.4 Hz, 2H), 6.98 
(dd, J = 19.8, 7.9 Hz, 4H), 5.63 (s, 2H), 3.74 (s, 3H), 2.77 (t, J = 7.5 Hz, 2H), 2.50 (t, J = 7.5 Hz, 2H); 
13C NMR (75 MHz, DMSO-d6) δ 173.81, 171.45, 166.95, 156.25, 155.57, 155.48, 134.32, 130.68, 
129.45 122.33, 114.93, 113.90, 64.31, 55.21, 35.44, 29.50. HRMS (ESI) m/z calcd for C20H19N3O5SNa 
[M+Na+] 436.0937, found 436.0938. 
 
4.2.3.3. 3-[4-({5-[(2-Fluorophenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic 
acid (7c). Compound 7c was obtained as a white  solid (116 mg, 58%). M. p. 198-201 °С; 1H NMR (300 
MHz, DMSO-d6) δ 12.12 (s, 1H), 10.94 (s, 1H), 7.61 (t, J = 7.7 Hz, 1H), 7.33 (dd, J = 8.3, 3.7 Hz, 2H), 
7.25 (dd, J = 7.4, 4.2 Hz, 1H), 7.19 (d, J = 8.4 Hz, 2H), 7.02 (d, J = 8.5 Hz, 2H), 5.66 (s, 2H), 2.77 (t, J 
= 7.5 Hz, 2H), 2.50 (t, J = 7.5 Hz, 2H); 13C NMR (75 MHz, DMSO-d6) δ 173.65, 171.71, 165.70, 156.17, 
155.69 (d, J = 248.09 Hz), 155.40, 134.30, 129.36, 127.80 (d, J = 8.31 Hz), 126.95 (d, J = 1.21 Hz), 
124.43 (d, J = 3.63 Hz), 124.08 (d, J = 12.28 Hz), 115.93 (d, J = 19.55 Hz), 114.91, 64.26, 35.35, 29.43. 
HRMS (ESI) m/z calcd for C19H16FN3O4SNa [M+Na+] 424.0737, found 424.0738. 
4.2.3.4. 3-[4-({5-[(3-Methylphenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic 
acid (7d). Compound 7d was obtained as a white  solid (107 mg, 54%). M. p. 185-189 °С; 1H NMR 
(300 MHz, DMSO-d6) δ 11.10 (s, 1H), 7.69 (s, 1H), 7.62 (d, J = 8.2 Hz, 1H), 7.25 (t, J = 7.8 Hz, 1H), 
7.19 (d, J = 8.5 Hz, 2H), 7.00 (t, J = 8.0 Hz, 3H), 5.64 (s, 2H), 2.77 (t, J = 7.5 Hz, 2H), 2.50 (t, J = 7.5 
Hz, 2H), 2.31 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 173.65, 171.48, 166.69, 155.90, 155.43, 137.92, 
137.48, 134.28, 129.35, 128.51, 125.39, 121.27, 117.99, 114.89, 64.28, 35.35, 29.43, 21.12. HRMS 
(ESI) m/z calcd for C20H19N3O4SNa [M+Na+] 420.0988, found 420.0988. 
 
4.2.3.5. 3-[4-({5-[(4-Fluorophenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic 
acid (7e). Compound 7e was obtained as a white  solid (116 mg, 58%). M. p. 192-197 °С; 1H NMR (300 
MHz, DMSO-d6) δ 12.12 (s, 1H), 11.28 (s, 1H), 7.87 (dd, J = 9.0, 5.0 Hz, 2H), 7.29 – 7.14 (m, 4H), 7.01 
(d, J = 8.5 Hz, 2H), 5.64 (s, 2H), 3.56 (s, 3H), 2.77 (t, J = 7.5 Hz, 2H), 2.50 (t, J = 7.4 Hz, 2H); 13C NMR 
(75 MHz, DMSO-d6) δ 173.65, 171.57, 166.54, 158.84 (d, J = 241.69 Hz), 155.92, 155.42, 134.29, 
133.96 (d, J = 2.59 Hz), 129.35, 122.72 (d, J = 8.13 Hz), 115.36 (d, J = 22.49 Hz), 114.90, 64.28, 35.35, 
29.43. HRMS (ESI) m/z calcd for C19H16FN3O4SNa [M+Na+] 424.0737, found 424.0738 
 
4.2.3.6. 3-[4-({5-[(2-methylphenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic 
acid (7f). Compounds 7f was obtained as a white  solid (111 mg, 56%). M. p. 188-192°С; 1H NMR (300 
MHz, DMSO-d6) δ 12.12 (s, 1H), 10.71 (s, 1H), 7.42 – 7.36 (m, 1H), 7.31 – 7.25 (m, 1H), 7.25 – 7.21 
(m, 2H), 7.19 (d, J = 8.5 Hz, 2H), 7.01 (d, J = 8.6 Hz, 2H), 5.65 (s, 2H), 2.77 (t, J = 7.5 Hz, 2H), 2.50 
(t, J = 7.5 Hz, 2H), 2.25 (s, 3H); 13C NMR (75 MHz, DMSO-d6) δ 173.78, 171.57, 166.45, 156.15, 
155.45, 134.85, 134.31, 133.59, 130.46, 129.45, 126.69, 126.36, 126.16, 114.92, 64.24, 35.42, 29.48, 
17.76. HRMS (ESI) m/z calcd for C20H19N3O4SNa [M+Na+] 420.0988, found 420.0988. 
 
4.2.3.7. 3-[4-({5-[(4-chlorophenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic 
acid (7g). Compound 7g was obtained as a white  solid (131 mg, 63%). M. p. 220-222°С; 1H NMR (300 
MHz, DMSO-d6) δ 12.12 (s, 1H), 11.35 (s, 1H), 7.88 (d, J = 8.9 Hz, 2H), 7.44 (d, J = 8.8 Hz, 2H), 7.19 
(d, J = 8.5 Hz, 2H), 7.01 (d, J = 8.6 Hz, 2H), 5.64 (s, 2H), 2.77 (t, J = 7.5 Hz, 2H), 2.50 (t, J = 7.5 Hz, 
2H); 13C NMR (75 MHz, DMSO-d6) δ 173.78, 171.77, 165.60, 156.14, 155.45, 136.67, 134.33, 129.44, 
128.72, 128.48, 122.36, 114.92, 64.31, 35.44, 29.49. HRMS (ESI) m/z calcd for C19H16ClN3O4SNa 
[M+Na+] 440.0442, found 440.0442. 
 
4.2.3.8. 3-[4-({5-[(3-fluorophenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic 
acid (7h). Compound 7h was obtained as a white solid (110 mg, 55%). M. p. 177-181°С; 1H NMR (300 
MHz, DMSO-d6) δ 12.12 (s, 1H), 11.40 (s, 1H), 7.81 – 7.66 (m, 2H), 7.41 (dd, J = 15.2, 8.1 Hz, 1H), 
7.19 (d, J = 8.6 Hz, 2H), 7.07 – 6.94 (m, 3H), 5.65 (s, 2H), 2.77 (t, J = 7.5 Hz, 2H), 2.50 (t, J = 7.5 Hz, 
2H); 13C NMR (75 MHz, DMSO-d6) δ 173.67, 171.77, 166.33, 161.92 (d, J = 241.69 Hz), 156.24, 
155.43, 139.33 (d, J = 10.90 Hz), 134.31, 130.38 (d, J = 9.34 Hz), 129.36, 116.55 (d, J = 2.77 Hz), 
114.91, 111.22 (d, J = 21.10 Hz), 107.56 (d, J = 26.29 Hz), 64.31, 35.36, 29.45. HRMS (ESI) m/z calcd 
for C19H16FN3O4SNa [M+Na+] 424.0737, found 424.0738. 
 
4.2.3.9. 3-[4-({5-[(3-methoxyphenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic 
acid (7i). Compound 7i was obtained as a white solid (128 mg, 62%). M. p. 156-160°С; 1H NMR (300 
MHz, DMSO-d6) δ 12.14 (s, 1H), 11.15 (s, 1H), 7.52 (s, 1H), 7.46 (d, J = 7.9 Hz, 1H), 7.27 (t, J = 8.1 
Hz, 1H), 7.19 (d, J = 8.3 Hz, 1H), 7.01 (d, J = 8.3 Hz, 2H), 6.75 (d, J = 7.9 Hz, 1H), 5.64 (s, 2H), 3.75 
(s, 3H), 2.77 (t, J = 7.3 Hz, 2H), 2.50 (t, J = 7.2 Hz, 2H); 13C NMR (75 MHz, DMSO-d6) δ 173.67, 
171.57, 166.65, 159.40, 155.97, 155.44, 138.75, 134.30, 129.51, 129.36, 114.91, 112.94, 110.19, 106.59, 
64.30, 55.02, 35.37, 29.45. HRMS (ESI) m/z calcd for C20H19N3O5SNa [M+Na+] 436.0937, found 
436.0938. 
 
4.2.3.10. 3-[4-({5-[(3,4-difluorophenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propa-
noic acid (7j). Compound 7j was obtained as a white solid (147 mg, 70%). M. p. 208-213°С; 1H NMR 
(300 MHz, DMSO-d6) δ 12.12 (s, 1H), 11.44 (s, 1H), 7.95 (ddd, J = 12.9, 7.4, 2.3 Hz, 1H), 7.73 – 7.62 
(m, 1H), 7.46 (dd, J = 19.6, 9.3 Hz, 1H), 7.19 (d, J = 8.5 Hz, 2H), 7.01 (d, J = 8.5 Hz, 2H), 5.64 (s, 2H), 
2.77 (t, J = 7.5 Hz, 2H), 2.49 (t, J = 7.3 Hz, 2H); 13C NMR (75 MHz, DMSO-d6) δ 173.66, 171.79, 
166.21, 156.17, 155.42, 148.78 (dd, J = 13.32 Hz, 243.59 Hz), 146.15 (dd, J = 12.63 Hz, 243.59 Hz), 
134.62 (dd, J = 2.94 Hz, 9.17 Hz), 134.31, 129.35, 117.45 (d, J = 17.48 Hz), 117.28 (dd, J = 3.63 Hz, 
5.36 Hz), 114.90, 109.88 (d, J = 21.80 Hz),64.29, 35.36, 29.43. HRMS (ESI) m/z calcd for 
C19H15F2N3O4SNa [M+Na+] 442.0643, found 442.0644. 
 4.2.3.11. 3-[4-({5-[(4-methylphenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propanoic 
acid (7k). Compound 7k was obtained as a white solid (107 mg, 54%). M. p. 185-189 °С; 1H NMR (300 
MHz, DMSO-d6) δ 12.11 (s, 1H), 11.12 (s, 1H), 7.72 (d, J = 8.4 Hz, 2H), 7.18 (dd, J = 8.3, 3.6 Hz, 4H), 
7.01 (d, J = 8.5 Hz, 2H), 5.64 (s, 2H), 2.77 (t, J = 7.5 Hz, 2H), 2.50 (t, J = 7.5 Hz, 3H), 2.26 (d, J = 12.0 
Hz, 3H); 13C NMR (75 MHz, DMSO-d6) δ 173.79, 171.54, 166.86, 155.81, 155.47, 135.15, 134.31, 
133.87, 129.44, 129.17, 120.75, 114.93, 64.30, 35.43, 29.49, 20.55. HRMS (ESI) m/z calcd for 
C20H19N3O4SNa [M+Na+] 420.0988, found 420.0988. 
 
4.2.3.12. 3-[4-({5-[(3-chlorophenyl)carbamoyl]-1,3,4-thiadiazol-2-yl}methoxy)phenyl]propa-noic 
acid (7l). Compound 7l was obtained as a white solid (113 mg, 54%). M. p. 171-173 °С; 1H NMR (300 
MHz, DMSO-d6) δ 12.10 (s, 1H), 11.39 (s, 1H), 8.00 (s, 1H), 7.81 (d, J = 8.2 Hz, 1H), 7.41 (t, J = 8.1 
Hz, 1H), 7.25 – 7.15 (m, 3H), 7.01 (d, J = 8.6 Hz, 2H), 5.65 (s, 2H), 2.77 (t, J = 7.5 Hz, 2H), 2.50 (t, J 
= 7.5 Hz, 2H); 13C NMR (75 MHz, DMSO-d6) δ 173.78, 171.88, 166.38, 156.33, 155.45, 139.15, 134.33, 
133.04, 130.50, 129.44, 124.49, 120.27, 119.24, 114.92, 64.30, 35.43, 29.48. HRMS (ESI) m/z calcd for 
C19H16ClN3O4SNa [M+Na+] 440.0442, found 440.0442. 
4.3 Molecular modeling 
4.3.1. Protein structure source and preparation for docking 
The crystal structure of FFA1 complexed with TAK-875, with PDB code: 4phu was used for docking 
studies.25 All in silico work pertaining to docking and protein preparation was carried out using the 
specified modules within Schrodinger's maestro, version 2016-1.26 To prepare FFA1 for docking, 
hydrogens, missing atoms and alternate residue positions were defined followed by optimization of the 
hydrogen bonding network by re-orienting hydroxyl and amide groups of Asn and Gln and identifying 
an appropriate orientation of the imidazole ring of His residues using Protein Preparation Wizard.27 
4.3.2. Docking protocol. 
The mutant Ala88 made for thermal stability during crystallization was mutated back to Phe followed 
by extensive sampling for the side-chain position. Careful positioning of the phenyl group was needed 
as Phe88 can be considered as an import residue in stabilizing protein-ligand binding and may influence 
docking results substantially. The conformation was sampled using MacroModel's Conformational 
Search.28 To alleviate any protein strain occurring from this point mutation, while reducing deviation 
from the original crystal structure coordinates, a tightly controlled, two stage minimization protocol was 
applied, i.e. hydrogen only minimization followed by a minimization based on constraints set from the 
Commented [DM9]: I don’t believe it makes sense to have 
separate subtitle for docking protocol, as protein preparation is 
contained in both. 
X-ray derived B factors. MinimisationMinimization was performed using MacroModel.28 In deciding 
on a final position of Phe88 and ensuring a correct docking protocol was used, TAK-875 was re-docked 
onto the receptor and compared to the position obtained in the crystal structure, an RMSD of < 2.5 Å. 
Prior to docking, agonists were created manually in maestro, the 2D structures were then optimized to 
produce a low-energy 3D structure using LigPrep.29 Glide30 was used for receptor grid generation and 
ligand docking. The centroid of the receptor grid was defined by using TAK-875's crystal structure 
conformation. Ligands were docked using the extra precision (XP) algorithm while enhancing the 
planarity of conjugated pi groups. The OPLS3, all-atom force-field was employed for all calculations. 
In labelling the protein residues of FFA1 in figure 4 and figure 5 the number in subscript represents the 
Ballesteros Weinstein indexing system.21 
4.4 Biological and ADME assays 
4.4.1. Determination of agonistic activity of compounds against GPR40, GPR41, GPR43 and 
GPR120 receptors 
CHO cells stably expressing GPCRs (CHO-GPR40 purchased from The European Collection of Cell 
Cultures, ECACC) were seeded (12500cells/well) into 384-well black-wall, clear-bottom microtiter 
plates 24 h prior to assay. Cells were loaded for 1 h with calcium assay kit and tested using fluorometric 
imaging plate reader (FLIPR Tetra High Throughput Cellular Screening System  by Molecular Devices). 
Maximum change in fluorescence over base line was used to determine agonist response. A potent and 
selective agonist for FFA1 (GPR40) GW9508 (Selleckchem, S8014) was tested with the test compounds 
as a positive control. Concentration response curve data were fitted using Molecular Devices 
ScreenWorks® System Control Software (Molecular Devices).  
For specificity screening for possible GPR41, 43 and 120 agonism, CHO cell lines stably expressing the 
respective receptors (also purchased from The European Collection of Cell Cultures, ECACC) were 
used. 
4.4.2. Determination of the distribution coefficient (LogD, pH 7.4) 
The partitioning ratio of compounds 6a, 6c, 7c and 7l and one reference compound (logDpH7 = 2.93) was 
determined in n-octanol – phosphate buffer saline (PBS) using shake-flask method which consists of 
equilibrating a certain amount of a solute within the biphasic system and determining the concentration 
in each phase using LC-MS/MS. Equilibration was carried out in Eppendorf-type polypropylene 
microtubes in duplicates. 5 µL aliquots of 10 mM DMSO stock solution were added to a manually pre-
equilibrated mixture of PBS (500 µL) and n-octanol (500 µL) and the resulting mixture was shaken for 
1h at 30 rpm. Phase separation was achieved by centrifugation for 2 min at 6000 rpm. The n-octanol 
phase was diluted 100-fold with 40% aqueous acetonitrile and the PBS phase was diluted 10-fold with 
5% aqueous acetonitrile. The partitioning ratio (D) was calculated using the formula: 
, 
where S0 – peak area of the analyte in the n-octanol phase, Sp – peak area of the analyte in PBS phase. 
4.4.3. Assessment of metabolic stability in mouse liver microsomes 
The metabolic stability of compound 6a, 6c, 7c and 7l as well as the reference compound (Propranolol) 
was measured in liver microsomes at five time points over 40 minutes using HPLC-MS. Metabolic 
stability is defined as the percentage loss of parent compound  lost over time in the presence of a 
metabolically active test system, such as rodent liver microsomal fractions.  
Mouse hepatic microsomes were isolated from pooled (50), perfused livers of BALB/c male mice 
according to the standard protocol.31  The batch of microsomes was tested for quality control using a 
commercial comparator preparation (Sigma-Aldrich M9441) and verapamil as reference compound. 
Microsomal incubations were carried out in 96-well plates in 5 aliquots of 40 μL each (one for each time 
point). Liver microsomal incubation medium contained potassium phosphate buffer (100 mM, pH 7.4), 
MgCl2 (3.3 mM), NADPН (3 mM), glucose-6-phosphate (5.3 mM), glucose-6-phosphate 
dehydrogenase (0.67 units/ml) with 0.42 mg of liver microsomal protein per ml. In addition, control 
incubations were performed replacing the NADPH-regenerating system with 100 mM phosphate buffer 
pH 7.4. Test compounds (2 μM, final solvent concentration 1.6 %) were incubated at 37°C under 
vortexing at 100 rpm. Five time points over 40 minutes had been analyzed. The reactions were stopped 
by adding 12 volumes of 90% acetonitrile-water to 40 μL incubation aliquots, followed by plasma 
protein precipitation by centrifuging at 5500 rpm for 3 minutes. Incubations were performed in 
duplicates. Supernatants were analyzed using the HPLC system coupled with tandem mass spectrometer. 
The elimination constant (kel), half-life (T1/2) and intrinsic clearance (Clint) were determined in plot of 
ln(AUC) versus time, using linear regression analysis:  
kel = - slope 
T1/2 = 0.693/kel 
CLint = (0.693/ T1/2) x (µl incubation/mg microsomes) 
4.4.4. Analysis of mouse plasma protein binding 
The binding of compound 6a, 6c, 7c and 7l as well as the reference compound (Verapamil) to mouse 
plasma proteins was evaluated using HPLC-MS/MS. The task was performed by spiking test compounds 
at concentration of 1 μM into mice plasma (Lampire Biological Labs, US, catalog number 7304309) and 
dialyzing against buffer until equilibrium is achieved. Concentrations of the compounds in both plasma 
and buffer were determined to calculate the percentage of plasma protein bound compounds. 
The assay was performed in the 96-well equilibrium dialysis apparatus (HTDialysis, LLC). Each 
individual well unit consisted of 2 chambers separated by a vertically aligned dialysis membrane of 
predetermined pore size (MWCO 12-14 kDa). 120 μl of plasma spiked with the compound (1 μM, final 
solvent concentration 1%) was added to one chamber and the same aliquot of PBS buffer, pH 7.4 was 
added to the other chamber. After that, HTD96b dialyzer was covered with adhesive sealing film and 
incubated at 37°C on an orbital shaker at 100 rpm for 5 hours. An aliquot of the content of each chamber 
had been taken and mixed with the same volume aliquot of the blank opposite matrix. In order to define 
non-specific loss of the compound during this assay, standard solution was created by mixing an aliquot 
of spiked plasma, which was incubated at 37°C without dialysis, with blank buffer. Sample of 1 μM 
series was diluted with 100% acetonitrile 10-fold with subsequent plasma proteins precipitation by 
centrifuging at 6000 rpm for 5 minutes. Incubations were performed in quadriplicates. Supernatants were 
analyzed using HPLC system coupled with tandem mass spectrometer. The unbound compound fraction 
is calculated as the peak ratio of the analyte in the buffer compartment divided by the same parameter 
in the corresponding plasma compartment. 
The following equation was used to determine the extent of plasma protein binding: 
 
 
4.4.5. Analysis of stability in mouse plasma 
Five 40 µL aliquots of 1 µM solution (final DMSO concentration 1%) of each of the compounds (6a, 
6c, 7c, 7l and two reference compounds – verapamil and propantheline) were incubated with mouse 
plasma (Lampire Biological Labs, US, catalog number 7304309) at 37 °C with shaking at 100 rpm. Five 
time points over 120 min were analyzed. The reactions were stopped by the addition of acetonitrile (200 
µL) and the plasma proteins were sedimented by 5 min centrifugation at 5500 rpm. Supernatants were 
analyzed by LC-MS/MS. The percentage of the test compounds remaining after incubation in plasma 
and their half-lives (T1/2) were determined. 
4.4.6. CYP450 inhibition 
The inhibition of major CYP450 isoforms (1A2, 2C9, 2C19, 2D6, 3A4) by compounds 6a, 6c, 7c and 7l 
at a 20 μM concentration was evaluated using P450-Glo™ Assay Systems (Promega) in accordance with 
the manufacturer’s protocols. A conventional cytochrome P450 reaction was performed by incubating 
the cytochrome P450 and a luminogenic cytochrome P450 substrate. All test points were performed in 
quadruplicates. Control membranes (without CYPs) represent the Negative control (baseline). DMSO 
final concentration was 0.25%. The following reference compounds were used to assess CYP inhibition: 
CYP Reference inhibitor Concentration , µM % inhibition 
1A2 α-Naphthoflavone 4 99.21 
2C9 Fluconazole 120 89.09 
2C19 Omeprazole 24 93.40 
2D6 Quinidine 1 96.25 
3A4 Ketoconazole 20 95.37 
Concentrations of alfa-naphthoflavone, quinidine, ketoconazole, fluconazole and omeprazole are shown 
as 4x of Promega protocol recommendations or 4x of their IC50 found in the literature.32-33 
4.4.7. hERG binding 
Assessment of compounds’ binding to hERG (human Ether-a-go-go-Related Gene) channel was 
performed using PredictorTM hERG Fluorescence Polarization Assay kit (Invitrogen, US, catalog 
number PV5365) according to manufacturer’s protocol. The hERG reaction was performed by 
incubating the tracer (a small fluorescent molecule) and cell membranes containing hERG channel with 
the solutions of the test compounds (1 µM, 5 µM, 20 µM) for 4 hours. The difference of fluorescence 
polarization from the maximal value (no compound) was used as a measure of compound’s binding to 
hERG channel. A strong hERG binder (compound E-4031 provided as a part of the test kit) was used as 
a positive control (it’s reported IC50 value is 70 nM was confirmed experimentally prior to carrying out 
the testing). All measurement were performed in quandruplicates. 
 
Acknowledgements 
This research was supported by the Russian Scientific Fund (project grant 14-50-00069). We are grateful 
to the Center for Chemical Analysis and Materials Research of Saint-Petersburg State University for 
providing high-resolution mass-spectrometry data. 
Supplementary data 
Supplementary data associated with this article can be found, in the online version, at 
http://dx.doi.org/xxx. 
 
References and notes 
1. Briscoe, C. P.; Tadayyon, M.; Andrews, J. L.; Benson, W. G.; Chambers, J. K.; Eilert, M. M.; Ellis, 
C.; Elshourbagy, N. A.; Goetz, A. S.; Minnick, D. T.; Murdock, P. R.; Sauls, H. R.; Shabon, U.; Spinage, 
L. D.; Strum, J. C.; Szekeres, P. G.; Tan, K. B.; Way, J. M.; Ignar, D. M.; Wilson, S.; Muir, A. I. J. Biol. 
Chem. 2003, 278, 11303−11311.  
2. Itoh, Y.; Kawamata, Y.; Harada, M.; Kobayashi, M.; Fujii, R.; Fukusumi, S.; Ogi, K.; Hosoya, M.; 
Tanaka, Y.; Uejima, H.; Tanaka, H.; Maruyama, M.; Satoh, R.; Okubo, S.; Kizawa, H.; Komatsu, H.; 
Matsumura, F.; Noguchi, Y.; Shinohara, T.; Hinuma, S.; Fujisawa, Y.; Fujino, M. Nature 2003, 422, 
173-176.  
3. Watterson, K. R.; Hudson, B. D.; Ulven, T.; Milligan, G. Front. Endocrinol. 2014, 5, 137. 
4. Defossa, E.; Wagner, M. Bioorg. Med. Chem. Lett. 2014, 24, 2991-3000. 
5. https://clinicaltrials.gov, last accessed on March 7, 2016. 
6. Kaku, K.; Enya, K.; Nakaya, R.; Ohira, T.; Matsuno, R. Diabetes Obes. Metab. 2015, 17, 675-681. 
7. Mancini, A. D.; Poitout, V. Diabetes Obes. Metab. 2015, 17, 622-629. 
8. Lin, D. C.-H.; Zhang, J.; Zhuang, R.; Li, F.; Nguyen, K.; Chen, M.; TRan, T.; Lopez, E.; Lu, J. Y. 
L.; Li, X. N.; Tang, L.; Tonn, G. R.; Swaminath, G.; Reagan, J. D.; Chen, J.-L.; Tian, H.; Lin, Y.-J.; 
Houze, J. B.; Luo, J. PlosOne 2011, 6, e27270. 
9. Zahanich, I.; Kondratov, I.; Naumchyk, V.; Kheylik, Y.; Platonov, M.; Zozulya, S.; Krasavin, M. 
Bioorg. Med. Chem. Lett. 2015, 25, 3105-3111. 
10. Maekawa, T.; Hara, R.; Odaka, H.; Fukatsu, K.; Mizufune, H. PCT Int. Appl. WO 2003099793A1; 
Chem. Abstr. 2003, 140, 951003. 
11. Hamamura, K.; Sasaki, S.; Amano, Y.; Sakamoto, J.; Fukatsu, K. PCT Int. Appl. WO 
2004022551A1; Chem. Abstr. 2004, 140, 220326. 
12. Yasuma, T.; Negoro, N.; Sasaki, S. PCT Int. Appl. WO 2005087710 A1; Chem. Abstr. 2005, 143, 
1021733. 
13. Rharma, R.; Akerman, M.; Cardozo, M. G.; Houze, J.; Li, A.-R.; Liu, J.; Liu, J.; Ma, Z.; Medina, 
J.C.; Schmitt, M. J.; Sun, Y.; Wang, Y.; Wang, Z.; Zhu, L. PCT Int. Appl. WO 2007106469 A2; Chem. 
Abstr. 2007, 147, 1064386. 
14. Krasavin, M.; Lukin, A.; Zhurilo, N.; Kovalenko, A.; Zahanich, I.; Zozulya, S. J. Enzyme Inhib. 
Med. Chem. 2016, DOI: 10.3109/14756366.2016.1142984. 
15. Negoro, N.; Sasaki, S.; Mikami, S.; Ito, M.; Suzuki, M.; Tsujihata, Y.; Ito, R.; Harada, A.; Takeuchi, 
K.; Suzuki, N.; Miyazaki, J.; Santou, T.; Odani, T.; Kanzaki, N.; Funami, M.; Tanaka, T.; Kogame, A.; 
Matsunaga, S.; Yasuma, T.; Momose, Y. ACS Med. Chem. Lett. 2010, 1, 290-294. 
16. Calculations were performed using ACD/Labs 6.00 software. 
17. Yarovenko, V. N.; Shirokov, A. V.; Krupinova, O. N.; Zavarzin, I. V.; Krayushkin M. M. Russ. J. 
Org. Chem. 2003, 39, 1133-1139. 
18. Ichimura, A.; Hirasawa, A.; Hara, T.; Tsujimoto, G. Prostaglandins Other Lipid Mediat. 2009, 89, 
82–88. 
19. Brown, J. A.; Goldsworthy, S. M.; Barnes, A. A.; Ellert, M. M.; Tcheang, L.; Daniels, D.; Muir, A. 
I.; Wogglesworth, M. J.; Kinghorn, I.; Fraser, N. J.; Pike, N. B.; Sturn, J. C.; Steplewski, K. M; Murdoch, 
P. R.; Holder, J. C.; Marshall, F. H.; Szekeres, P. G.; Wilson, S.; Ignar, D. M.; Foord, M. S.; Wise, A.; 
Dowell, S. J. J. Biol. Chem. 2003, 278, 11312-11319. 
20. Hirasawa, A.; Tsumaya, K.; Awaji, T.; Katsuma, S.; Adachi, T.; Yamada, M.; Sugimoto, Y.; 
Miyazaki, S.; Tsujimoto, G. Nat. Med. 2005, 11, 90-94. 
21. Ballesteros, J.; Weinstein, H. Biophys. J. 1995, 68, A446. 
22. Ritchie, T. J.; Macdonald, S. J. F. Drug Discov. Today 2009, 14, 1011-1020. 
23. Yoshimoto, K.; Echizen, H.; Chiba, K.; Tani, M.; Ishizaki, T. Br. J. Clin. Pharmacol. 1995, 39, 421-
431. 
24. Braenden, G.; Sjoegren, T.; Schnecke, V.; Xue, Y. Drug Discov. Today 2014, 19, 905-911. 
25. Srivastava, A.; Yano, J.; Hirozane, Y.; Kefala, G.; Gruswitz, F.; Snell, G.; Lane, W.; Ivetac, A.; 
Aertgeerts, K.; Nguyen, J.; Jennings, A.; Okada, K. Nature 2014, 513, 124-129. 
26. Schrödinger, Maestro version 10.5, LLC, New York, NY, 2016. 
27. Sastry, G. M.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W.  J. Comput. Aid. Mol. Des. 
2013, 27, 221–234. 
28. Schrödinger, Macromodel version 11.1, LLC, New York, NY, 2016. 
29. Schrödinger, Ligprep version 3.7, LLC, New York, NY, 2016. 
30. Friesner, R. A.; Banks, J. L.; Murphy, R. B.; Halgren, T. A.; Klicic, J. J.; Mainz, D. T.; Repasky, 
M. P.; Knoll, E. H.; Shelley, M.; Perry, J. K.; Shaw, D. E.; Francis, P.; Shenkin, P. S. J. Med. Chem. 
2004, 47, 1739-1749. 
31. Hill, J. R. In Current Protocols in Pharmacology 7.8.1-7.8.11, Wiley Interscience, 2003. 
32. Li, X.-Q.; Andersson, T. B.; Ahlström M.; Weidolf, L. Drug Metab. Dispos. 2004, 32, 821-827; 
33. Niwa, T.; Shiraga, T.; Takagi, A. Biol. Pharm Bull. 2005, 28, 1805-1808. 
